Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate
Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate
复制标题
DOI：
10.1111/j.1445-5994.2009.01947.x
复制
发表时间：
2009-06-01
影响因子：
2.1
通讯作者：
Oshimi, K.
中科院分区：
文献类型：
--
作者：
Isobe, Y.;Sugimoto, K.;Oshimi, K.
甲磺酸伊马替尼（IM）是目前治疗慢性粒细胞白血病（CML）的首选药物。由于IM难以穿透血脑屏障，IM治疗的CML患者可能有中枢神经系统（CNS）受累的潜在风险。在这里，我们报告了一例细菌性脑膜炎后仅在中枢神经系统中分离出淋巴母细胞危象的病例，尽管该患者通过IM治疗实现并维持了完全的细胞遗传学反应。在IM治疗的CML患者中，重要的是将孤立的CNS原始细胞危象视为可能的事件。
Imatinib mesylate (IM) is currently used as the first therapeutic choice against chronic myelogenous leukaemia (CML). Because IM poorly penetrates the blood-brain barrier, IM-treated CML patients may have a potential risk of central nervous system (CNS) involvement. Here we report a case with lymphoid blast crisis isolated only in CNS after bacterial meningitis, although the patient achieved and maintained complete cytogenetic response by IM therapy. It is important to consider isolated CNS blast crisis as a possible event in IM-treated CML patients.